| answer text |
<p>The objective of the pre-negotiation workshops was to enable a mutual understanding
of the impact of the current voluntary scheme upon the different organisations represented,
and to discuss the potential objectives and priorities for a new voluntary scheme.
The discussions in the workshops will feed into the upcoming negotiation of a successor
to the 2019 voluntary scheme for branded medicines pricing and access. In order to
facilitate a transparent and candid discussion, participants agreed that all contributions
would be kept confidential to those who attended.</p><p>The following external organisations
were invited to the workshops:</p><p>Industry bodies:</p><p>- Association of the British
Pharmaceutical Industry</p><p>- British Generic Manufacturers Association</p><p>-
Ethical Medicines Industry Group</p><p>- BioIndustry Association</p><p>Patient organisations
and civil society organisations:</p><p>- Cancer52</p><p>- The Blood Cancer Alliance</p><p>-
The Charity Medicines Access Coalition</p><p>- National Voices</p><p>- The Patients
Association</p><p>- Alzheimer’s Research UK</p><p>- Anthony Nolan</p><p>- Cystic Fibrosis
Trust</p><p>- Genetic Alliance UK</p><p>- The Association of Medical Research Charities</p><p>-
Breast Cancer Now</p><p>- Myeloma UK</p><p>- Office of Health Economics</p><p>- King’s
Fund</p><p>- NHS Confederation</p><p> </p>
|
|
